Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-287 (Jeimmugen) vs Mouse Brain-derived JE Vaccine in Children
NCT01150942Phase 3Completed
- Sponsor
- Boryung
- Start
- Aug 2010
- Primary completion
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ENCEVAC in Japanese encephalitis (JE) (2 arms), sponsored by Boryung. Primary endpoint: Immunogenicity (Seroconversion Rate and Geometric Mean Titer). Started Aug 2010; status: completed.
02
Drugs
ENCEVAC
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT01150942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01150942.